ABSTRACT
Objective To explore the levels of secretory phospholipase A2 (sPLA2) and lysophosphatidic acid (LPA) in blood and cerebrospinal fluid of patients with multiple sclerosis (MS), and to explore the relationship between the levels of these inflammatory biomarkers and disease activity of MS. Methods Blood samples were collected from 21 MS patients of acute period (acute period of MS group), 20 MS patients of remitting period (remitting period of MS group) and 21 patients with non inflammatory and vascular neurologic disease (control group). The levels of sPLA2 and LPA in blood and cerebrospinal fluid were measured and compared. Results The levels of sPLA2 and LPA in blood and cerebrospinal fluid before treatment in acute period of MS group were significantly higher than those in remitting period of MS group (P<0.01) and in control group (P<0.01). The levels of sPLA2 and LPA in blood and cerebrospinal fluid after treatment were significantly lower than those before treatment in acute period of MS group (P<0.01). The levels of sPLA2 and LPA in blood before and after treatment had correlations in acute period of MS group (r=0.962, P=0.000;r=0.848, P=0.000). The levels of sPLA2 and LPA in cerebrospinal fluid before and after treatment had correlations in the acute period group (r=0.968, P=0.000;r=0.850, P=0.000). Conclusions The levels of sPLA2 and LPA in blood and cerebrospinal fluid may be used as inflammatory biomarkers for disease activity in MS patients.
ABSTRACT
Objective To investigate whether Bushen-Huoxue compound adjuvant therapy can be effective on mild cognitive impairment in Parkinson's disease and the influence on plasma phospholipids(PLs) levels. Methods 87 PD patients were recruited and collected for the general information. The patients were evaluated by Unified Parkinson's Disease Rating Scale(UPDRS) Ⅲ and Montreal Cognitive Assessment(MoCA). According to MoCA scores, patients with PD-MCI were divided into a Bushen-Huoxue compound treatment group and a control group(basic L-dopa or dopamine agonist). Reevaluating cognitive function by MoCA and plasma phopholipids levels at posttreatment 12 month and 18 month. Plasma PLs was assayed by measuring its inorganic phosphorus after separation by chromatograph.Results 39 cases in 87 PD patients(44.8%)were with PD-MCI.After 12 months or 18 months treatment period, MoCA scores was significantly higher in Bushen-Huoxue compound treatment group than in controls(P<0.05 or 0.01 respectively). Plasma PLs levels were significantly decreased in Bushen-Huoxue compound treatment group than in controls(P<0.01 or 0.01 respectively). Conclusions Bushen-Huoxue compound could be effective in the adjuvant treatment of PD-MCI, and could delay cognitive rate of decline in patients with PD. Meanwhile, Bushen-Huoxue compound could significantly decrease plasma PLs levels in PD-MCI. The evidence from present study suggested that Bushen-Huoxue compound have neuroprotective effects on patients with PD-MCI.
ABSTRACT
Objective: To observe the characteristics of dynamic changes of lysophosphatidic acid (LPA) levels in cerebrospinal fluid (CSF) in patients with subarachnoid hemorrhage (SAH) and its relationship with cerebral vasospasm (CVS) and to explore the pathogenesis of CVS. Methods: Sixty-seven patients with SAH diagnozed by clinical and accessory examinations were selected. The LPA levels in CSF were measured at 24 hours, day 7,14, and 28 respectively after the onset of symptoms,and they were compared with a control group. The correlation between LPA levels and CVS on the time course was also observed at the same time. Results: Of the 67 patients with SAH, a total of 29 patients (43.3%) occurred CVS, the average time of occurrence was 6. 6 days. There was no significant difference between the LPA levels in CSF in patients with SAH and the control group at 24 hours after the onset of symptoms; they were significantly higher than the control group at day 7 (P ＜0. 001); they were significantly higher than the control group at day 14 (P ＜ 0. 001), but they were significantly lower than those at day 7 (P ＜ 0. 01); they decreased to baseline at day 28, and there was significant difference compared with the control group. There was no significant difference between the LPA levels in the CVS group and those in the non-CVS group at 24 hours, they were significantly higher than those in the non-CVS group at day 7 (P ＜0. 001), they were still significantly higher than those in the non-CVS group at day 14 (P ＜0. 01); and there was no significant difference between the 2 groups at day 28. Conclusions: The LPA levels in CSF in patients with SAH increased significantly from day 7 to day 14 after the onset of symptoms, and they had obvious association with CVS on the time course. The detection of the LPA levels in CSF may have important significance in predicting the occurrence of CVS.